(April 16, 2020, Shanghai) Recently, Wanbang Biopharmaceuticals (hereinafter referred to as "Wanbang Biopharma"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma", stock code: 600196.SH, 02196.HK) received the "Approval Document on Drug Supplementary Application" of Febuxostat Tablets (Trade name: Youlitong?, Strength: 40mg, 80mg) issued by NMPA, indicated that Febuxostat Tablets passed Consistency Evaluation of Generic Drugs.

Gout and related diseases caused by hyperuricemia are one of the chronic diseases with high incidence in China. According to the "China Guidelines for the Treatment of Hyperuricemia and Gout 2019", the prevalence of hyperuricemia in China is as high as 13.3%. Febuxostat Tablets are mainly indicated for the long-term treatment of hyperuricemia in patients with gout. In 2019, Wanabang Pharma’s sales revenue of Febuxostat Tablets in China were approximately RMB 1.126 billion. As of March 2020, Wanbang Biopharma has invested approximately RMB 21.42 million (unaudited) in R&D for the consistency evaluation.

Youlitong? (Febuxostat tablets) successfully passed generic drug consistency evaluation, which is conducive to improving product competitiveness, enhancing product market position, and bringing new market opportunities.